No abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34357/1/1178_ftp.pd

Bang, Yung‐Jue

Cho, Yong‐Baik

Heo, Dae Seog

Kim, Dae‐Kee

Kim, Key H.

Kim, Noe Kyeong

Kim, Tae‐You

Lee, Jung Ae

Park, Young Iee

Shin, Sang‐Goo

Cancer

James E. Montie

John T. Wei

Crossref

Artificial neural networks for prostate carcinoma risk assessment

BACKGROUND: Hospital mortality after esophagectomy has decreased from 29% to 7.5% over the last decades because of improved surgical techniques and better perioperative care. Suggestions have been made that a further decrease in hospital mortality may be achieved by centralization of esophagectomies in high volume centers.METHODS: The effect of hospital volume on hospital mortality after esophagectomy in the Netherlands was analyzed based on data from the Dutch National Medical Registry and the Dutch Network and National Database for Pathology over the period 1993-1998.RESULTS: Annually, approximately 310 (range, 264-321) esophagectomies are performed in the Netherlands. Fifty-two percent are performed in 43-55 low volume centers (1-10 resections a year). Six percent are performed in 1-3 medium volume centers (11-20 resections a year). The remainder (42%) is performed in two high volume centers (&gt; 50 resections a year). Hospital mortality is 12.1%, 7.5% and 4.9% respectively (P &lt; 0.001). The high volume centers seem to see slightly more advanced tumors than the low and medium volume centers.CONCLUSIONS: There is a significant (inverse) relation between hospital mortality and hospital volume for esophageal resection in the Netherlands. Although hospital mortality is not the only measure for quality of care, these data suggest a potential beneficial effect to centralization of esophagectomy in the Netherlands.</p

van Lanschot, J J

Hulscher, J B

Buskens, C J

Tilanus, H W

ten Kate, F J

Obertop, H

Dissertations of the University of Groningen

Hospital volume and hospital mortality for esophagectomy

BACKGROUND. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a rapidly developing new imaging technique in the diagnosis and staging of melanoma. The objective of the current study was to determine the diagnostic accuracy of FDG-PET in patients with melanoma. METHODS. A systematic review and meta-analysis of clinical studies regarding FDG-PET and cutaneous melanoma was conducted. Studies were identified by a comprehensive search of the MEDLINE, EMBASE, and Current Contents databases, without any language restrictions. Eleven studies were selected. The methodologic quality of these studies was assessed independently by two reviewers. Levels of evidence and grades of recommendation were determined for each study. Six studies could be included in the statistical pooling. Sources of heterogeneity were studied by meta-regression of the diagnostic odds ratio (DOR). A summary receiver operating characteristic curve was calculated. RESULTS. The pooled sensitivity and specificity of FDG-PET in the detection of melanoma metastases were 0.79 (95% confidence interval [95% CI], 0.66-0.93) and 0.86 (95% CI, 0.78-0.95), respectively. The pooled DOR of 33.1 (95% CI, 21.9-54.0) suggests a high diagnostic accuracy for PET. Subgroup analysis revealed that PET is more accurate for systemic staging (DOR of 36.4) than for regional staging (DOR of 19.5). When used for regional staging, PET performed better in patients with American Joint Committee on Cancer Stage III disease, compared with patients with Stage I and Stage II disease. However, the methodologic quality of the studies was limited. Major problems were verification, review, and selection bias. CONCLUSIONS. Due to the poor methodologic quality of the available studies, to the authors' knowledge it is yet not possible to develop guidelines for the effective use of PET in patients with melanoma. Future accuracy studies should meet the methodologic criteria outlined in the current review

Mijnhout, G. Sophie

Hoekstra, Otto S.

Van Tulder, Maurits W.

Teule, Gerrit J.J.

Devillé, Walter L.J.M.

NARCIS 

Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in melanoma patients

Proceedings - University of Groningen

van Lanschot, JJB

Hulscher, JBF

Buskens, CJ

Tilanus, Hugo

ten Kate, FJW

University of Groningen

BACKGROUND. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a rapidly developing new imaging technique in the diagnosis and staging of melanoma. The objective of the current study was to determine the diagnostic accuracy of FDG-PET in patients with melanoma. METHODS. A systematic review and meta-analysis of clinical studies regarding FDG-PET and cutaneous melanoma was conducted. Studies were identified by a comprehensive search of the MEDLINE, EMBASE, and Current Contents databases, without any language restrictions. Eleven studies were selected. The methodologic quality of these studies was assessed independently by two reviewers. Levels of evidence and grades of recommendation were determined for each study. Six studies could be included in the statistical pooling. Sources of heterogeneity were studied by meta-regression of the diagnostic odds ratio (DOR). A summary receiver operating characteristic curve was calculated. RESULTS. The pooled sensitivity and specificity of FDG-PET in the detection of melanoma metastases were 0.79 (95% confidence interval [95% CI], 0.66-0.93) and 0.86 (95% CI, 0.78-0.95), respectively. The pooled DOR of 33.1 (95% CI, 21.9-54.0) suggests a high diagnostic accuracy for PET. Subgroup analysis revealed that PET is more accurate for systemic staging (DOR of 36.4) than for regional staging (DOR of 19.5). When used for regional staging, PET performed better in patients with American Joint Committee on Cancer Stage III disease, compared with patients with Stage I and Stage II disease. However, the methodologic quality of the studies was limited. Major problems were verification, review, and selection bias. CONCLUSIONS. Due to the poor methodologic quality of the available studies, to the authors' knowledge it is yet not possible to develop guidelines for the effective use of PET in patients with melanoma. Future accuracy studies should meet the methodologic criteria outlined in the current review.</p

VU Research Portal

Systematic review of the diagnostic accuracy of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography in melanoma patients

https://doi.org/10.1002/1097-0142(20010415)91:8<1530::aid-cncr1162>3.0.co;2-%23

Artificial neural networks for prostate carcinoma risk assessment

Abstract

Similar works

Full text

Available Versions

Crossref

Dissertations of the University of Groningen

Dissertations of the University of Groningen

NARCIS

NARCIS

Proceedings - University of Groningen

NARCIS

University of Groningen

VU Research Portal